Lineage Cell Therapeutics (LCTX) Reports In-Line Q3 EPS

Lineage Cell Therapeutics (NYSE: LCTX) reported Q3 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $2.27 million versus the consensus estimate of $510 thousand.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.

You May Also Be Interested In

• Trump discloses over $1.4 billion in crypto income in 2025 filing
• Belden completes acquisition of Ruckus Networks from Vistance
• FactSet (FDS) Tops Q3 EPS by 8c ; Offers Guidance